Sanofi (SNY) Non-Current Deferred Tax Liability (2009 - 2026)

Sanofi has reported Non-Current Deferred Tax Liability for 18 years, with the latest figure at $1.8 billion in Q2 2026.

• Quarterly Non-Current Deferred Tax Liability fell 7.01% year-over-year to $1.8 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.8 billion (down 7.01% YoY) and the FY2025 annual result came in at $1.9 billion, down 16.21% from the prior year.
• Non-Current Deferred Tax Liability slipped to $1.8 billion in Q2 2026 per SNY's latest filing, from $1.9 billion in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $2.3 billion in Q4 2024 and troughed at $1.7 billion in Q2 2022.
• A 5-year average of $2.0 billion and a median of $1.9 billion in 2025 frame the typical range for Non-Current Deferred Tax Liability.
• The sharpest annual moves came in 2022 and 2023: Non-Current Deferred Tax Liability dropped 17.96% in 2022, then rose 28.38% in 2023.
• Over 5 years, Non-Current Deferred Tax Liability stood at $1.9 billion in 2022, then advanced by 6.38% to $2.0 billion in 2023, then increased by 15.84% to $2.3 billion in 2024, then fell by 16.21% to $1.9 billion in 2025, then dropped by 6.92% to $1.8 billion in 2026.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $1.8 billion, $1.9 billion, and $1.9 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.